title: Electroconductive lithotripsy: principles, experimental data, and first clinical results of the Sonolith 4000.
abstract: The electroconductive lithotripter (ECL) is a new concept for shockwave generation in which a highly conductive solution channels the discharge between the anode and cathode. In vitro experiments showed a linear relation between the voltage setting and the pressure at F2. In vitro stone disintegration studies showed a considerable reduction in shockwave pressure variability, improved energy transfer to the stone, and a unique linear relation between fragmentation and electrode voltage without a saturation effect. This new concept has been used clinically in the Sonolith 4000 lithotripter. In 142 evaluable treatments with a 3-month follow-up, the overall stone-free rate was 82%, and the retreatment rate in stone-free patients was 10%. For stones equal or less than 10 mm, the 3-month stone-free rate, retreatment rate, and secondary procedure rate were 85%, 5%, and 0%, respectively. For stones between 11 and 20 mm, these figures were 83%, 4%, and 2%, respectively. The efficiency quotient was found to be 81% for stones equal or less than 10 mm and 78% for stones between 11 and 20 mm. These clinical results confirm the improvements in efficacy observed in vitro with very satisfactory tolerance.
authors.affiliation: Department of Urology, Cochin Hospital, Paris, France.
authors.forename: T A
authors.initials: TA
authors.lastname: Flam
authors.forename: M
authors.initials: M
authors.lastname: Bourlion
authors.forename: N
authors.initials: N
authors.lastname: Thiounn
authors.forename: F
authors.initials: F
authors.lastname: Saporta
authors.forename: R
authors.initials: R
authors.lastname: Chiche
authors.forename: P
authors.initials: P
authors.lastname: Dancer
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.forename: B
authors.initials: B
authors.lastname: Debré
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D007669:Kidney Calculi / Q000473:pathology / Q000628:therapy*; D007670:Kidney Calices; D007682:Kidney Pelvis; D008096:Lithotripsy / Q000009:adverse effects / Q000379:methods; D010316:Particle Size; D016896:Treatment Outcome; D014514:Ureteral Calculi / Q000473:pathology / Q000628:therapy*